ibr900
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 24, 2021 (NCT05271279)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07073833 | Phase 1 | Jul 20, 2025 | Imbioray (Hangzhou) Biomedicine Co., Ltd. |
| NCT05411757 | Early Phase 1 (Phase 1) | Jun 30, 2022 | Imbioray (Hangzhou) Biomedicine Co., Ltd., Shandong University |
| NCT05271279 | Early Phase 1 (Phase 1) | Dec 24, 2021 | Beijing Boren Hospital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imbioray (Hangzhou) Biomedicine Co., Ltd. | For profit | 2 | 1 | 1 | 2022 |
| Beijing Boren Hospital | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2022 |
3 organizations
Page 1 / 1